SEC Company Response from Aptevo Therapeutics Inc. (APVO) (CIK 0001671584) (APVO) — Apr 15, 2016
Aptevo Therapeutics Inc. (APVO) (CIK 0001671584)
Date: April 15, 2016 · CIK: 0001671584 · Accession: 0001193125-16-543363
AI Filing Summary & Sentiment
Reasoning
Letter
Re:
April 15, 2016
BY EDGAR SUBMISSION
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Aptevo Therapeutics Inc.
Registration Statement on Form 10
Ladies and Gentlemen:
Submitted herewith for filing on behalf of Aptevo Therapeutics Inc. (the “Company”), a wholly owned subsidiary of Emergent BioSolutions Inc. (“Emergent”), is a Registration Statement on Form 10 relating to the registration under Section 12(b) of the Securities Exchange Act of 1934, as amended, of the Company’s common stock, par value $0.001 per share (the “Registration Statement”).
This filing is being effected by direct transmission to the Commission’s EDGAR System.
The Registration Statement relates to the proposed distribution by Emergent to its stockholders of all of the shares of the Company’s common stock, as more fully described in the Registration Statement.
Please contact the undersigned at (617) 526-6461 or Joseph B. Conahan at (617) 526-6317 with any questions or comments you may have regarding this filing.
Very truly yours,
/s/ Hal J. Leibowitz
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
April 15, 2016
BY EDGAR
SUBMISSION
Securities and Exchange Commission
100 F
Street, N.E.
Washington, DC 20549
Re:
Aptevo Therapeutics Inc.
Registration Statement
on Form 10
Ladies and Gentlemen:
Submitted herewith for filing on behalf of Aptevo Therapeutics Inc. (the “Company”), a wholly owned subsidiary of Emergent BioSolutions Inc.
(“Emergent”), is a Registration Statement on Form 10 relating to the registration under Section 12(b) of the Securities Exchange Act of 1934, as amended, of the Company’s common stock, par value $0.001 per share (the
“Registration Statement”).
This filing is being effected by direct transmission to the Commission’s EDGAR System.
The Registration Statement relates to the proposed distribution by Emergent to its stockholders of all of the shares of the Company’s common stock, as
more fully described in the Registration Statement.
Please contact the undersigned at (617) 526-6461 or Joseph B. Conahan at (617) 526-6317
with any questions or comments you may have regarding this filing.
Very truly yours,
/s/ Hal J. Leibowitz
Hal J. Leibowitz
cc:
A.B. Cruz, III, Esq., Executive Vice President and General Counsel,
Emergent BioSolutions Inc.
Eric M.
Burt, Esq., Vice President and Associate General Counsel Legal Affairs and
Compliance Division, Emergent BioSolutions
Inc.
Joseph B. Conahan, Esq., Wilmer Cutler Pickering Hale and Dorr LLP